✦ LIBER ✦

Effects of receptor tyrosine kinase inhibitor A47 on estrogen and growth factor-dependent breast cancer cell proliferation and apoptosis in vitro

✍ Scribed by Jane M. Turbov; George M. Twaddle; Xiaohe Yang; Naxin M. Liu; Satya Murthy

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 205 KB
Volume: 79
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.10033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

✍ Nicholas B. Lydon; Helmut Mett; Marcel Mueller; Michael Becker; Robert M. Cozens 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 243 KB 👁 2 views

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 1 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int. J. Cancer,76, 154–163 (1998)

✍ N. Lydon; H. Mett; M. Mueller; M. Becker; R.M. Cozens; D. Daniels; P. Traxler; E 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 8 KB 👁 2 views

Targeted inhibition of the epidermal gro

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells

✍ Alessandro Sgambato; Andrea Camerini; Beatrice Faraglia; Raffaele Ardito; Gabrie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (‘Iressa’), an orally a

Characterization of the effects of the n

Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro

✍ Jacques Simard; Claude Labrie; Alain Bélanger; Sylvain Gauthier; Shankar M. Sing 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 256 KB 👁 2 views

Since estrogens play a predominant role in the development and growth of human breast cancer, antiestrogens represent a logical approach to the treatment of this disease. The present study compares the effects of the novel nonsteroidal anti-estrogen EM-800 and related compounds with those of a serie

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell